ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-39.67	-27.76	-28.12	-64.42	-60.74	-46.57
Depreciation & Amortization	2.71	2.76	2.51	2.52	2.33	2.36
Loss (Gain) From Sale of Assets	-	-	-0.13	-	-	-
Loss (Gain) From Sale of Investments	-	-	-	-	-0.51	-
Loss (Gain) on Equity Investments	-	-	-	0.01	0.22	0.32
Stock-Based Compensation	2.85	2.54	3.11	2.87	6.22	7.84
Other Operating Activities	-0.77	-0.67	-4.78	-4.49	1.47	-5.54
Change in Unearned Revenue	-12.73	-12.73	-6.47	-2.99	-	-
Change in Other Net Operating Assets	5.4	-0.54	55.43	-2	25.01	-5.47
Operating Cash Flow	-42.2	-36.39	21.55	-68.51	-26.01	-47.06
Capital Expenditures	-0.74	-1.42	-1.37	-0.71	-0.48	-0.92
Sale of Property, Plant & Equipment	-	-	0.06	0.01	0.06	-
Sale (Purchase) of Intangibles	-	-	7.94	-	-	-
Other Investing Activities	-2.66	-2.66	-2.35	-	-	-
Investing Cash Flow	13.6	-4.07	4.28	-0.7	-0.43	-0.92
Long-Term Debt Issued	-	-	-	-	27.66	14.37
Long-Term Debt Repaid	-	-1.58	-2.63	-45.05	-0.82	-0.61
Net Debt Issued (Repaid)	-1.57	-1.58	-2.63	-45.05	26.84	13.77
Issuance of Common Stock	71.75	71.86	0.35	14.16	110	0.74
Financing Cash Flow	70.18	70.28	-2.28	-30.89	136.83	14.5
Foreign Exchange Rate Adjustments	-0.79	0.67	0.6	7.35	1.29	-2.63
Net Cash Flow	40.8	30.48	24.15	-92.75	111.69	-36.11
Free Cash Flow	-42.95	-37.81	20.18	-69.22	-26.5	-47.98
Free Cash Flow Margin	-250.57%	-193.46%	305.99%	-1587.89%	-1114.21%	-4663.17%
Free Cash Flow Per Share	-0.44	-0.44	0.25	-0.97	-0.41	-0.96
Cash Interest Paid	0.65	0.77	0.79	3.76	2.25	1.11
Cash Income Tax Paid	0.02	-0.2	-0.08	0.1	0.12	0.19
Levered Free Cash Flow	-25.38	-18.04	62.8	-99.16	-16.21	-27.45
Unlevered Free Cash Flow	-24.71	-17.37	63.56	-95.96	-14.09	-26.18
Change in Working Capital	-7.33	-13.26	48.96	-4.99	25.01	-5.47

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q